Skip to main content
SpringerLink
Log in

Pharmacological Challenges in Neurocritical Care

  • Chapter
  • First Online:
Neurointensive Care Unit

Part of the book series: Current Clinical Neurology ((CCNEU))

  • 1397 Accesses

Abstract

Neurointensivists often face the challenge of providing care for critically ill patients with complicated medical conditions. Many pharmacological agents such as anticonvulsants, antimicrobials, anticoagulants, antiplatelets, sedatives, analgesics, hyperosmolar therapy, and neuromuscular blocking agents may need to be initiated or resumed in this setting. The already altered physiology of critically ill patients combined with factors such as obesity as well as interventions such as renal replacement therapy (RRT), extracorporeal membrane oxygenation (ECMO), and plasma exchange (PLEX) may lead to therapeutic failure or toxicity. It is therefore crucial for neurocritical care providers to be familiar with the pharmacokinetic and pharmacodynamic changes of commonly used medications in the neurocritical care setting and apply these principles to clinical practice. It is clear that optimal management of pharmacological agents in neurocritical care is challenging given altered physiology and non-pharmacological interventions listed above. Providing education on such topics and approaching patient care in a multi-disciplinary fashion where clinical pharmacists are actively involved is invaluable.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Owusu KA, Hamilton L. 22.1 Pharmacokinetics in neurocritical care. In: Neurocritical care for the advanced practice clinician. Springer International Publishing; 2017. p. 407.

    Google Scholar 

  2. Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. Crit Care Clin. 2006;22(2):255–71.

    Article  CAS  PubMed  Google Scholar 

  3. Johnston JD, Harvey CJ, Menzies IS, Treacher DF. Gastrointestinal permeability and absorptive capacity in sepsis. Crit Care Med. 1996;24(7):1144–9.

    Article  CAS  PubMed  Google Scholar 

  4. Ronchera-Oms CL, Tormo C, Ordovas JP, Abad J, Jimenez NV. Expanded gentamicin volume of distribution in critically ill adult patients receiving total parenteral nutrition. J Clin Pharm Ther. 1995;20(5):253–8.

    Article  CAS  PubMed  Google Scholar 

  5. Boucher BA, Rodman JH, Jaresko GS, Rasmussen SN, Watridge CB, Fabian TC. Phenytoin pharmacokinetics in critically ill trauma patients. Clin Pharmacol Ther. 1988;44(6):675–83.

    Article  CAS  PubMed  Google Scholar 

  6. Wilkinson GR, Shand DG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975;18(4):377–90.

    Article  CAS  PubMed  Google Scholar 

  7. McKindley DS, Hanes SD, Boucher BA. Hepatic drug metabolism in critical illness. Pharmacotherapy. 1998;18(4):759–78.

    CAS  PubMed  Google Scholar 

  8. Wermeling DP, Blouin RA, Porter WH, Rapp RP, Tibbs PA. Pentobarbital pharmacokinetics in patients with severe head injury. Drug Intell Clin Pharm. 1987;21(5):459–63.

    Article  CAS  PubMed  Google Scholar 

  9. Eisenberg HM, Frankowski RF, Contant CF, Marshall LF, Walker MD, Comprehensive Central Nervous System Trauma Centers. High-dose barbiturate control of elevated intracranial pressure in patients with severe head injury. J Neurosurg. 1988;69(1):15–23.

    Article  CAS  PubMed  Google Scholar 

  10. McKindley DS, et al. Effect of acute phase response on phenytoin metabolism in neurotrauma patients. J Clin Pharmacol. 1997;37(2):129–39.

    Article  CAS  PubMed  Google Scholar 

  11. Joy MS, Matzke GR, Armstrong DK, Marx MA, Zarowitz BJ. A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother. 1998;32(3):362–75.

    Article  CAS  PubMed  Google Scholar 

  12. Ashley C, Morlidge C, editors. Introduction to renal therapeutics. London: Pharmaceutical Press; 2008.

    Google Scholar 

  13. Velenosi TJ, Urquhart BL. Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis. Expert Opin Drug Metab Toxicol. 2014;10(8):1131–43.

    Article  CAS  PubMed  Google Scholar 

  14. Susla GM. The impact of continuous renal replacement therapy on drug therapy. Clin Pharmacol Ther. 2009;86(5):562–5.

    Article  CAS  PubMed  Google Scholar 

  15. Fissell WH. Antimicrobial dosing in acute renal replacement. Adv Chronic Kidney Dis. 2013;20(1):85–93.

    Article  PubMed  Google Scholar 

  16. Shekar K, Fraser JF, Smith MT, Roberts JA. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care. 2012;27(6):741–e9.

    Article  PubMed  CAS  Google Scholar 

  17. Elliott ES, Buck ML. Phenobarbital dosing and pharmacokinetics in a neonate receiving extracorporeal membrane oxygenation. Ann Pharmacother. 1999;33(4):419–22.

    Article  CAS  PubMed  Google Scholar 

  18. Shekar K, Roberts JA, Mcdonald CI, Ghassabian S, Anstey C, Wallis SC, Mullany DV, Fung YL, Fraser JF. Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study. Crit Care. 2015;19(1):164.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Erstad BL. Designing drug regimens for special intensive care unit populations. World J Crit Care Med. 2015;4(2):139.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Ibrahim RB, Liu C, Cronin SM, Murphy BC, Cha R, Swerdlow P, Edwards DJ. Drug removal by plasmapheresis: an evidence-based review. Pharmacotherapy. 2007;27(11):1529–49.

    Article  CAS  PubMed  Google Scholar 

  21. Silberstein LE, Shaw LM. Effect of plasma exchange on phenytoin plasma concentration. Ther Drug Monit. 1986;8:172–6.

    Article  CAS  PubMed  Google Scholar 

  22. Barras M, Legg A. Drug dosing in obese adults. Aust Prescr. 2017;40(5):189.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71–87.

    Article  CAS  PubMed  Google Scholar 

  24. Kendrick JG, Carr RR, Ensom MH. Pharmacokinetics and drug dosing in obese children. J Pediatr Pharmacol Ther. 2010;15(2):94–109.

    PubMed  PubMed Central  Google Scholar 

  25. Brill MJ, Diepstraten J, van Rongen A, Van Kralingen S, van den Anker JN, Knibbe CA. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51(5):277–304.

    Article  CAS  PubMed  Google Scholar 

  26. Han PY, Duffull SB, Kirkpatrick CM, Green B. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther. 2007;82(5):505–8.

    Article  CAS  PubMed  Google Scholar 

  27. Ingrande J, Lemmens HJ. Dose adjustment of anaesthetics in the morbidly obese. Br J Anaesth. 2010;105:i16–23.

    Article  CAS  PubMed  Google Scholar 

  28. Pai MP. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kidney Dis. 2010;17(5):e53–62.

    Article  PubMed  Google Scholar 

  29. Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, LaRoche SM, Riviello JJ, Shutter L, Sperling MR, Treiman DM. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3–23.

    Article  PubMed  Google Scholar 

  30. Kluwer W. 2017; Lexicomp online. Available at: (Accessed May 31, 2018) http://www.wolterskluwercdi.com/lexicomp-online/View in Article.

  31. Corman C, Guberman A, Benavente O. Clobazam in partial status epilepticus. Seizure. 1998;7(3):243–7.

    Article  CAS  PubMed  Google Scholar 

  32. Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology. 1984;61(1):27–35.

    Article  CAS  PubMed  Google Scholar 

  33. Wulfsohn NL. Ketamine dosage for induction based on lean body mass. Anesth Analg. 1972;51(2):299–305.

    Article  CAS  PubMed  Google Scholar 

  34. Cross SA, Curran MP. Lacosamide: in partial-onset seizures. Drugs. 2009;69(4):449–59.

    Article  CAS  PubMed  Google Scholar 

  35. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43(11):707–24.

    Article  CAS  PubMed  Google Scholar 

  36. Wilkes L, Danziger LH, Rodvold KA. Phenobarbital pharmacokinetics in obesity. Clin Pharmacokinet. 1992;22(6):481–4.

    Article  CAS  PubMed  Google Scholar 

  37. Smetana KS, Cook AM, Bastin ML, Oyler DR. Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy. J Crit Care. 2016;36:116–24.

    Article  PubMed  Google Scholar 

  38. Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, Bare M, Bleck T, Dodson WE, Garrity L, Jagoda A. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American Epilepsy Society. Epilepsy Curr. 2016;16(1):48–61.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Suemaru K, Kawasaki H, Yasuhara K, Yao K, Furuno K, Kawakami Y, Araki H, Gomita Y, Oka E. Steady-state serum concentrations of carbamazepine and valproic acid in obese and lean patients with epilepsy. Acta Med Okayama. 1998;52(3):139–42.

    CAS  PubMed  Google Scholar 

  40. Shekar K, Roberts JA, Mcdonald CI, Fisquet S, Barnett AG, Mullany DV, Ghassabian S, Wallis SC, Fung YL, Smith MT, Fraser JF. Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Crit Care. 2012;16(5):R194.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Nei SD, Wittwer ED, Kashani KB, Frazee EN. Levetiracetam pharmacokinetics in a patient receiving continuous venovenous hemofiltration and venoarterial extracorporeal membrane oxygenation. Pharmacotherapy. 2015;35(8):e127.

    Article  PubMed  Google Scholar 

  42. Dzierba AL, Abrams D, Brodie D. Medicating patients during extracorporeal membrane oxygenation: the evidence is building. Crit Care. 2017;21(1):66.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Frontera JA, Lewin JJ III, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, Del Zoppo GJ, Kumar MA, Peerschke EI, Stiefel MF, Teitelbaum JS. Guideline for reversal of antithrombotics in intracranial hemorrhage. Neurocrit Care. 2016;24(1):6–46.

    Article  CAS  PubMed  Google Scholar 

  44. Muller C, Caillard S, Jesel L, El Ghannudi S, Ohlmann P, Sauleau E, Hannedouche T, Gachet C, Moulin B, Morel O. Association of estimated GFR with platelet inhibition in patients treated with clopidogrel. Am J Kidney Dis. 2012;59(6):777–85.

    Article  CAS  PubMed  Google Scholar 

  45. Beavers CJ, Heron P, Smyth SS, Bain JA, Macaulay TE. Obesity and antiplatelets-does one size fit all? Thromb Res. 2015;136(4):712–6.

    Article  CAS  PubMed  Google Scholar 

  46. Bonello-Palot N, Armero S, Paganelli F, et al. Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2009;104:1511–5.

    Article  CAS  PubMed  Google Scholar 

  47. Sibbing D, von Beckerath O, Schömig A, Kastrati A, von Beckerath N. Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am J Cardiol. 2007;100(2):203–5.

    Article  CAS  PubMed  Google Scholar 

  48. Darlington A, Tello-Montoliu A, Rollini F, Ueno M, Ferreiro JL, Patel R, Desai B, Guzman LA, Bass TA, Angiolillo DJ. Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease. Thromb Haemost. 2014;111(2):258–65.

    Article  CAS  PubMed  Google Scholar 

  49. Sebaaly J, Covert K. Enoxaparin dosing at extremes of weight: literature review and dosing recommendations. Ann Pharmacother. 2018;52(9):898–909. https://doi.org/10.1177/1060028018768449.

    Article  CAS  PubMed  Google Scholar 

  50. Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(6):1308–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Buckley LF, Rybak E, Aldemerdash A, Cheng JW, Fanikos J. Direct oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced age. Clin Cardiol. 2017;40(1):46–52.

    Article  PubMed  Google Scholar 

  52. Upreti VV, Wang J, Barrett YC, Byon W, Boyd RA, Pursley J, LaCreta FP, Frost CE. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol. 2013;76(6):908–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Güler E, Güler GB, Demir GG, Hatipoğlu S. A review of the fixed dose use of new oral anticoagulants in obese patients: is it really enough? Anatol J Cardiol. 2016;15(12):1020.

    Article  PubMed Central  Google Scholar 

  54. Phillips MR, Khoury AL, Ashton RF, Cairns BA, Charles AG. The dosing and monitoring of argatroban for heparin induced thrombocytopenia during extracorporeal membrane oxygenation: a word of caution. Anaesth Intensive Care. 2014;42(1):97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Scheld WM, Koedel U, Nathan B, Pfister HW. Pathophysiology of bacterial meningitis: mechanism (s) of neuronal injury. J Infect Dis. 2002;186(Suppl._2):S225–33.

    Article  CAS  PubMed  Google Scholar 

  56. Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, Whitley RJ. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39(9):1267–84.

    Article  PubMed  Google Scholar 

  57. Hong J, Krop LC, Johns T, Pai MP. Individualized vancomycin dosing in obese patients: a two-sample measurement approach improves target attainment. Pharmacotherapy. 2015;35(5):455–63.

    Article  CAS  PubMed  Google Scholar 

  58. Vance-Bryan K, Guay DR, Gilliland SS, Rodvold KA, Rotschafer JC. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother. 1993;37(3):436–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol. 1998;54(8):621–5.

    Article  CAS  PubMed  Google Scholar 

  60. Adane ED, Herald M, Koura F. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections. Pharmacotherapy. 2015;35(2):127–39.

    Article  CAS  PubMed  Google Scholar 

  61. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006;34(suppl_1):D668–72.

    Article  CAS  PubMed  Google Scholar 

  62. Preston TJ, Hodge AB, Riley JB, Leib-Sargel C, Nicol KK. In vitro drug adsorption and plasma free hemoglobin levels associated with hollow fiber oxygenators in the extracorporeal life support (ECLS) circuit. J Extra Corpor Technol. 2007;39(4):234.

    PubMed  PubMed Central  Google Scholar 

  63. Mehta NM, Halwick DR, Dodson BL, Thompson JE, Arnold JH. Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment. Intensive Care Med. 2007;33(6):1018–24.

    Article  CAS  PubMed  Google Scholar 

  64. Donadello K, Roberts JA, Cristallini S, Beumier M, Shekar K, Jacobs F, Belhaj A, Vincent JL, de Backer D, Taccone FS. Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy: a matched cohort study. Crit Care. 2014;18(6):632.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, Andes D. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006;50(4):1570–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Bakken JS, Cavalieri SJ, Gangeness D, Kubat T, Pollack JR. Influence of therapeutic plasmapheresis on elimination of ceftriaxone. Antimicrob Agents Chemother. 1993;37(5):1171–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Bozkurt F, Schollmeyer P, Keller E. Kinetics of ceftazidime during plasmapheresis. Eur J Clin Pharmacol. 1987;33(2):197–201.

    Article  CAS  PubMed  Google Scholar 

  68. Brophy DF, Mueller BA. Vancomycin removal by plasmapheresis. Ann Pharmacother. 1996;30(9):1038.

    Article  CAS  PubMed  Google Scholar 

  69. Osman BA, Lew SQ. Vancomycin removal by plasmapheresis. Basic Clin Pharmacol Toxicol. 1997;81(5):245–6.

    Article  CAS  Google Scholar 

  70. Foral PA, Heineman SM. Vancomycin removal during a plasma exchange transfusion. Ann Pharmacother. 2001;35(11):1400–2.

    Article  CAS  PubMed  Google Scholar 

  71. Turner RB, Cumpston A, Sweet M, Briggs F, Slain D, Wen S, Craig M, Hamadani M, Petros W. Prospective, controlled study of acyclovir pharmacokinetics in obese patients. Antimicrob Agents Chemother. 2016;60(3):1830–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Meng L, Mui E, Holubar MK, Deresinski SC. Comprehensive guidance for antibiotic dosing in obese adults. Pharmacotherapy. 2017;37(11):1415–31.

    Article  PubMed  Google Scholar 

  73. Payne KD, Hall RG. Dosing of antifungal agents in obese people. Expert Rev Anti-Infect Ther. 2016;14(2):257–67.

    Article  CAS  PubMed  Google Scholar 

  74. Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy. 2009;29(5):562–77.

    Article  CAS  PubMed  Google Scholar 

  75. Morad A, Farrokh S, Papangelou A. Pain management in neurocritical care; an update. Curr Opin Crit Care. 2018;24(2):72–9.

    Article  PubMed  Google Scholar 

  76. Barr J, Fraser GL, Puntillo K, Ely EW, Gélinas C, Dasta JF, Davidson JE, Devlin JW, Kress JP, Joffe AM, Coursin DB. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41(1):263–306.

    Article  PubMed  Google Scholar 

  77. Fong JJ, Sylvia L, Ruthazer R, Schumaker G, Kcomt M, Devlin JW. Predictors of mortality in patients with suspected propofol infusion syndrome. Crit Care Med. 2008;36(8):2281–7.

    Article  CAS  PubMed  Google Scholar 

  78. Tang JF, Chen PL, Tang EJ, May TA, Stiver SI. Dexmedetomidine controls agitation and facilitates reliable, serial neurological examinations in a non-intubated patient with traumatic brain injury. Neurocrit Care. 2011;15(1):175–81.

    Article  PubMed  CAS  Google Scholar 

  79. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manag. 2004;28(5):497–504.

    Article  CAS  Google Scholar 

  80. Remérand F, Le Tendre C, Baud A, Couvret C, Pourrat X, Favard L, Laffon M, Fusciardi J. The early and delayed analgesic effects of ketamine after total hip arthroplasty: a prospective, randomized, controlled, double-blind study. Anesth Analg. 2009;109(6):1963–71.

    Article  PubMed  CAS  Google Scholar 

  81. Reves JD, Fragen RJ, Vinik HR, Greenblatt DJ. Midazolam: pharmacology and uses. Anesthesiology. 1985;62(3):310–24.

    Article  CAS  PubMed  Google Scholar 

  82. Rostami-Hodjegan A, Wolff K, Hay AW, Raistrick D, Calvert R, Tucker GT. Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Clin Pharmacol. 1999;48(1):43–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Shibutani K, Inchiosa MA, Sawada K, Bairamian M. Pharmacokinetic mass of fentanyl for postoperative analgesia in lean and obese patients. Br J Anaesth. 2005;95(3):377–83.

    Article  CAS  PubMed  Google Scholar 

  84. Abernethy DR, Greenblatt DJ, Divoll M, Smith RB, Shader RI. The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. Clin Pharmacokinet. 1984;9(2):177–83.

    Article  CAS  PubMed  Google Scholar 

  85. Furlan V, Hafi A, Dessalles MC, Bouchez J, Charpentier B, Taburet AM. Methadone is poorly removed by haemodialysis. Nephrol Dial Transplant. 1999;14(1):254–5.

    Article  CAS  PubMed  Google Scholar 

  86. Leykin Y, Pellis T, Lucca M, Lomangino G, Marzano B, Gullo A. The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients. Anesth Analg. 2004;99(4):1086–9.

    Article  PubMed  Google Scholar 

  87. Obara S, Morimoto I, Iseki Y, Oishi R, Mogami M, Imaizumi T, Hosono A, Hakozaki T, Nakano Y, Isosu T, Murakawa M. The effect of obesity on dose of dexmedetomidine when administered with fentanyl during postoperative mechanical ventilation-retrospective. Fukushima J Med Sci. 2015;61(1):38–46.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Tellor B, Shin N, Graetz TJ, Avidan MS. Ketamine infusion for patients receiving extracorporeal membrane oxygenation support: a case series. F1000Res. 2015;4:16.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Lemaitre F, Hasni N, Leprince P, Corvol E, Belhabib G, Fillâtre P, Luyt CE, Leven C, Farinotti R, Fernandez C, Combes A. Propofol, midazolam, vancomycin and cyclosporine therapeutic drug monitoring in extracorporeal membrane oxygenation circuits primed with whole human blood. Crit Care. 2015;19(1):40.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Mulla H, Lawson G, Von Anrep C, Burke MD, Upton DU, Firmin RK, Killer H. In vitro evaluation of sedative drug losses during extracorporeal membrane oxygenation. Perfusion. 2000;15(1):21–6.

    Article  CAS  PubMed  Google Scholar 

  91. Bhatt-Mehta V, Annich G. Sedative clearance during extracorporeal membrane oxygenation. Perfusion. 2005;20(6):309–15.

    Article  Google Scholar 

  92. Wagner D, Pasko D, Phillips K, Waldvogel J, Annich G. In vitro clearance of dexmedetomidine in extracorporeal membrane oxygenation. Perfusion. 2013;28(1):40–6.

    Article  CAS  PubMed  Google Scholar 

  93. Suarez JI, Qureshi AI, Bhardwaj A, Williams MA, Schnitzer MS, Mirski M, Hanley DF, Ulatowski JA. Treatment of refractory intracranial hypertension with 23.4% saline. Crit Care Med. 1998;26(6):1118–22.

    Article  CAS  PubMed  Google Scholar 

  94. Kaneda K, Baker MT, Han TH, Weeks JB, Todd MM. Pharmacokinetic characteristics of bolus-administered mannitol in patients undergoing elective craniotomy. J Clin Pharmacol. 2010;50(5):536–43.

    Article  CAS  PubMed  Google Scholar 

  95. Gramstad L. Atracurium, vecuronium and pancuronium in end-stage renal failure: dose- response properties and interactions with azathioprine. Br J Anaesth. 1987;59(8):995–1003.

    Article  CAS  PubMed  Google Scholar 

  96. Kisor DF, Schmith VD, Wargin WA, Lien CA, Ornstein E, Cook DR. Importance of the organ-independent elimination of cisatracurium. Anesth Analg. 1996;83(5):1065–71.

    Article  CAS  PubMed  Google Scholar 

  97. Lemmens HJ, Brodsky JB. The dose of succinylcholine in morbid obesity. Anesth Analg. 2006;102(2):438–42.

    Article  CAS  PubMed  Google Scholar 

  98. Pühringer FK, Keller C, Kleinsasser A, Giesinger S, Benzer A. Pharmacokinetics of rocuronium bromide in obese female patients. Eur J Anaesthesiol. 1999;16(8):507–10.

    Article  PubMed  Google Scholar 

  99. Meyhoff CS, Lund J, Jenstrup MT, Claudius C, Sørensen AM, Viby-Mogensen J, Rasmussen LS. Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? Anesth Analg. 2009;109(3):787–92.

    Article  CAS  PubMed  Google Scholar 

  100. Schwartz AE, Matteo RS, Ornstein E, Halevy JD, Diaz J. Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. Anesth Analg. 1992;74(4):515–8.

    Article  CAS  PubMed  Google Scholar 

  101. Bentley JB, Borel JD, Vaughan RW, Gandolfi AJ. Weight, pseudocholinesterase activity, and succinylcholine requirement. Anesthesiology. 1982;57(1):48–9.

    Article  CAS  PubMed  Google Scholar 

  102. Salihoĝlu ZI, Demiroluk SE, Köse YI, Zengin K, Taskin M, Gökay BV. Neuromuscular effects of cisatracurium in morbidly obese patients. Middle East J Anaesthesiol. 2008;19:831–9.

    PubMed  Google Scholar 

  103. Leykin Y, Pellis T, Lucca M, Lomangino G, Marzano B, Gullo A. The effects of cisatracurium on morbidly obese women. Anesth Analg. 2004;99(4):1090–4.

    Article  CAS  PubMed  Google Scholar 

  104. Kirkegaard-Nielsen H, Helbo-Hansen HS, Lindholm P, Severinsen IK, Pedersen HS. Anthropometric variables as predictors for duration of action of atracurium-induced neuromuscular block. Anesth Analg. 1996;83(5):1076–80.

    Article  CAS  PubMed  Google Scholar 

  105. Murray MJ, DeBlock H, Erstad B, Gray A, Jacobi J, Jordan C, McGee W, McManus C, Meade M, Nix S, Patterson A. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med. 2016;44(11):2079–103.

    Article  CAS  PubMed  Google Scholar 

  106. Jurado L, Allison TA, Gulbis B, Farrington E. Drug overview. In: Casebook in clinical pharmacokinetics and drug dosing: McGraw Hill Professional, Springer International Publishing; 2014. p. 117.

    Google Scholar 

  107. Karambelkar A, Kasekar R, Palevsky PM. Perioperative pharmacologic management of patients with end stage renal disease. Semin Dial. 2015;28(4):392–6.

    Article  PubMed  Google Scholar 

  108. Aronoff GR. Drug prescribing in renal failure: ACP Press, Springer International Publishing; 2007.

    Google Scholar 

  109. Fodale V, Santamaria LB. Laudanosine, an atracurium and cisatracurium metabolite. Eur J Anaesthesiol. 2002;19(7):466–73.

    Article  CAS  PubMed  Google Scholar 

  110. Buscher H, Vaidiyanathan S, Al-Soufi S, Nguyen DN, Breeding J, Rycus P, Nair P. Sedation practice in veno-venous extracorporeal membrane oxygenation: an international survey. ASAIO J. 2013;59(6):636–41.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Critical Care and Surgery Pharmacy, Johns Hopkins Hospital, Baltimore, MD, USA

    Salia Farrokh

  2. Department of Pharmacy, Yale New Haven Hospital, New Haven, CT, USA

    Abdalla A. Ammar & Kent A. Owusu

Authors
  1. Salia Farrokh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abdalla A. Ammar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kent A. Owusu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Salia Farrokh .

Editor information

Editors and Affiliations

  1. Johns Hopkins University, Baltimore, MD, USA

    Sarah E. Nelson

  2. Johns Hopkins University, Baltimore, MD, USA

    Paul A. Nyquist

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Farrokh, S., Ammar, A.A., Owusu, K.A. (2020). Pharmacological Challenges in Neurocritical Care. In: Nelson, S., Nyquist, P. (eds) Neurointensive Care Unit. Current Clinical Neurology. Humana, Cham. https://doi.org/10.1007/978-3-030-36548-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-36548-6_6

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-36547-9

  • Online ISBN: 978-3-030-36548-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation